Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Quinoline‐n‐butylcyanoacrylate‐based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease

Kulkarni, Padmakar V., Roney, Celeste A., Antich, Peter P., Bonte, Frederick J., Raghu, Anjanapura V., Aminabhavi, Tejraj M.·2010·WIREs Nanomedicine and Nanobiotechnology

Abstract

A survey of research activity on nanoparticles (NPs) based on polymeric devices that could cross the blood–brain barrier (BBB) is given along with the presentation of our own data on the development of NPs of n‐butyl‐2‐cyanoacrylate (BCA) for brain delivery to aid the early diagnosis of Alzeimer's disease (AD), a neurodegenerative disorder of the elderly people, the most prevalent form of dementia. Typical data are presented on in vivo detection of amyloid peptides (Aβ) (amyloid plaques) that are used as targets for developing the biological markers for the diagnosis of AD. In order to develop efficient in vivo probes, polymeric n‐butyl‐2‐cyanoacrylate (PBCA) NPs have been prepared and encapsulated with the radio‐labeled amyloid affinity drug 125 I‐clioquinol (CQ, 5‐chloro‐7‐iodo‐8‐hydroxyquinoline) to improve the transport to brain and amyloid plaque retention of 125 I‐CQ using the NPs of PBCA. The 125 I‐CQ discriminately binds to the AD post‐mortem brain tissue homogenates versus control. 125 I‐CQ‐PBCA NPs labeled the Aβ plaques from the AD human post‐mortem frontal cortical sections on paraffin‐fixed slides. Storage phosphor imaging verified preferential uptake by AD brain sections compared to cortical control sections. The 125 I‐CQ‐PBCA NPs crossed the BBB in wild type mouse, giving an increased brain uptake measured in terms of % ID/g i.e., injected dose compared to 125 I‐CQ. Brain retention of 125 I‐CQ‐PBCA NPs was significantly increased in the AD transgenic mice (APP/PS1) and in mice injected with aggregated Aβ42 peptide versus age‐matched wild type controls. The results of this study are verified by in vivo storage phosphor imaging and validated by histopathological staining of plaques and select metal ions, viz. Fe 2+ and Cu 2+. The 125 I‐CQ‐PBCA NPs had more efficient brain entry and rapid clearance in normal mice and enhanced the retention in AD mouse brain demonstrating the ideal in vivo imaging characteristics. The 125 I‐CQ‐PBCA NPs exhibited specificity for Aβ plaques both in vitro and in vivo. This combination offered radio‐iodinated CQ‐PBCA NPs as the promising delivery vehicle for in vivo single photon emission tomography (SPECT) (123 I) or PET (124 I) amyloid imaging agent. The importance of the topic in relation to brain delivery and other similar type of work published in this area are covered to highlight the importance of this research to medical disciplines. WIREs Nanomed Nanobiotechnol 2010 2 35–47 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/wnan.59

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 159

Metadata

Authors
Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., & Aminabhavi, T. M.
Venue
WIREs Nanomedicine and Nanobiotechnology
Publisher
Wiley
Published
2009-12-14
Volume
2
Issue
1
Pages
35-47
ISSN
  • 1939-0041 (ISSN-L)
  • 1939-5116
OpenAlex
W2036126963
Cited by
159
References
9
FWCI
3.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quinoline‐n‐butylcyanoacrylate‐based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. https://app.cochat.ai/papers/10.1002/wnan.59
The paper
Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., & Aminabhavi, T. M. (2010). Quinoline‐n‐butylcyanoacrylate‐based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.59

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.